NRG1 and neoplasm: To date, there is only one published clinical trial involving lapatinib (EGF104911) that measured NRG1 level in tumours by immunohistochemistry (IHC), but they did not mention any correlation between NRG1 and clinical benefits from lapatinib monotherapy [34].